R&G PharmaStudies Co. Ltd. A (301333) — Cash Flow Reinvestment Rate
R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow Reinvestment Rate of 0.33x as of June 2022, reinvesting CN¥13.67 Million (capex CN¥5.24 Million plus investments CN¥8.43 Million) from operating cash flow of CN¥40.98 Million. Explore R&G PharmaStudies Co. Ltd. A capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
R&G PharmaStudies Co. Ltd. A Cash Flow Reinvestment Rate (2019–2025)
Historical reinvestment intensity for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Also explore 301333 current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year capital reinvestment analysis for R&G PharmaStudies Co. Ltd. A. For live market cap and broader valuation context, see 301333 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.71x | CN¥81.65 Million | CN¥114.20 Million | CN¥19.28 Million | ▲ +380.4% |
| 2024 | 0.15x | CN¥23.03 Million | CN¥154.76 Million | CN¥19.98 Million | ▼ -96.0% |
| 2023 | 3.76x | CN¥724.68 Million | CN¥192.56 Million | CN¥19.88 Million | ▲ +1417.0% |
| 2022 | 0.25x | CN¥32.37 Million | CN¥130.47 Million | CN¥20.83 Million | ▼ -61.5% |
| 2021 | 0.64x | CN¥73.87 Million | CN¥114.57 Million | CN¥38.28 Million | ▼ -39.9% |
| 2020 | 1.07x | CN¥47.33 Million | CN¥44.10 Million | CN¥25.48 Million | ▲ +126.5% |
| 2019 | 0.47x | CN¥49.03 Million | CN¥103.48 Million | CN¥26.00 Million | — |